Pathologic Complete Response
Pathologic Complete Response
Explore linked clinical trials. Standard reference: MESH:M00075824357 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response | Disease Attributes, Disease Progression, Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 2 | 2026-10-02 | NCT07856303 | |
| Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) | Disease Attributes, Disease Progression, Neoplasms by Histologic Type, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma | Recruiting | Not stated | 2026-10-02 | NCT07855926 | |
| Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC | Disease Attributes, Disease Progression, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Not applicable | 2026-09-25 | NCT07066189 | |
| Perioperative Adebrelimab for Locally Advanced Cervical Cancer | Disease Attributes, Disease Progression, Neoplasm, Residual, Neoplastic Processes, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Not yet recruiting | Phase 2 | 2026-09-10 | NCT07811375 | |
| Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study | Disease Attributes, Disease Progression, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, esophageal squamous cell carcinoma | Recruiting | Phase 2 | 2026-09-09 | NCT07808853 | |
| Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma | Disease Attributes, Disease Progression, Head and Neck Neoplasms, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, head and neck cancer, neoplasm | Recruiting | Not stated | 2026-08-31 | NCT06755567 | |
| Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer | Disease Attributes, Disease Progression, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Not yet recruiting | Phase 2 | 2026-08-24 | NCT07780877 | |
| Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study | Disease Attributes, Disease Progression, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 1 | 2026-08-14 | NCT06743555 | |
| Supervised Exercise During Neoadjuvant Chemotherapy for Breast Cancer | Atrophy, Disease Attributes, Disease Progression, Neoplasms by Site, Neurologic Manifestations, Neuromuscular Manifestations, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Sarcopenia, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, muscular atrophy, neoplasm, nervous system disorder, skin disorder | Not yet recruiting | Not applicable | 2026-08-13 | NCT07764341 | |
| Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC | Disease Attributes, Disease Progression, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 4 | 2026-08-10 | NCT07754812 | |
| Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma | Disease Attributes, Disease Progression, Head and Neck Neoplasms, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Not yet recruiting | Phase 2 | 2026-08-07 | NCT07752394 | |
| Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients | Disease Attributes, Disease Progression, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-07-16 | NCT05350722 | |
| Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients | CD4+/CD56+ hematodermic neoplasm, Disease Attributes, Disease Progression, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-07-01 | NCT07007052 | |
| Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer | Disease Attributes, Disease Progression, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Not yet recruiting | Not stated | 2026-06-29 | NCT07673211 | |
| Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma | Disease Attributes, Disease Progression, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, squamous cell lung carcinoma | Not yet recruiting | Phase 2 | 2026-06-01 | NCT07618793 | |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors | Adnexal Diseases, Cytopenia, Disease Attributes, Disease Progression, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hemic and Lymphatic Diseases, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, blood platelet disease, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cervix disorder, endocrine system disorder, endometrium neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, hematologic disorder, lung cancer, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, primary peritoneal carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, thrombocytopenia, uterine disorder | Recruiting | Phase 2 | 2026-05-14 | NCT07586826 | |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors | Cytopenia, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Disease Progression, Hemic and Lymphatic Diseases, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, blood platelet disease, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, hematologic disorder, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder, thrombocytopenia | Recruiting | Phase 2 | 2026-05-14 | NCT07586813 | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Disease Attributes, Disease Progression, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, angiosarcoma, breast cancer, breast disorder, breast neoplasm, neoplasm, sarcoma, skin disorder, triple-negative breast carcinoma, vascular cancer | Recruiting | Phase 2 | 2026-05-06 | NCT01042379 | |
| Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma | Disease Attributes, Disease Progression, Head and Neck Neoplasms, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-04-20 | NCT07538206 | |
| Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD) | Cognition Disorders, Cognitive Dysfunction, Disease Attributes, Disease Progression, Mild Cognitive Impairment, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cognitive disorder, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Active, not recruiting | Not applicable | 2026-04-09 | NCT02386670 | |
| Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer | Disease Attributes, Disease Progression, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Not yet recruiting | Phase 3 | 2026-03-16 | NCT07472868 | |
| Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment | Disease Attributes, Disease Progression, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not stated | 2026-03-11 | NCT05926024 | |
| Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Disease Progression, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Recruiting | Phase 2 | 2026-03-06 | NCT06647680 | |
| Relugolix + Enzalutamide Study in High-Risk Prostate Cancer | Disease Attributes, Disease Progression, Neoplasm, Residual, Neoplastic Processes, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 | 2026-03-05 | NCT06130995 | |
| Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors | Disease Attributes, Disease Progression, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Active, not recruiting | Early phase 1 | 2026-03-05 | NCT03832569 |